---
title: "CJC-1295"
canonical_url: https://peptidelibrary.app/library/cjc-1295
description: "GHRH analog. Catalog “CJC-1295” often means the DAC (Drug Affinity Complex) form that extends half-life via albumin binding. Not FDA-approved. WADA S2 (GHRH analogues)."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# CJC-1295

CJC-1295 (also called CJC-1295 with DAC or DAC:GRF) is a long-acting GHRH analog in the Growth Hormone Secretagogue class. CJC-1295 is a GHRH analog based on GRF(1-29) carrying four amino-acid substitutions that resist dipeptidyl peptidase-4 cleavage, plus a maleimidopropionyl group at the C-terminus.

GHRH analog. Catalog “CJC-1295” often means the DAC (Drug Affinity Complex) form that extends half-life via albumin binding. Not FDA-approved. WADA S2 (GHRH analogues).

Also known as: CJC-1295 with DAC, DAC:GRF, Modified GRF with DAC.

Categories: Fat Loss, Muscle/Recovery, Longevity, Experimental.

## Classification

- Type: Long-acting GHRH analog
- Mechanism class: Growth Hormone Secretagogue
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

CJC-1295 is a GHRH analog based on GRF(1-29) carrying four amino-acid substitutions that resist dipeptidyl peptidase-4 cleavage, plus a maleimidopropionyl group at the C-terminus. That reactive group forms a covalent bond with cysteine-34 of circulating serum albumin after injection, creating a long-lived depot and extending the half-life from minutes to days. It binds the pituitary GHRH receptor, raising cyclic AMP and stimulating growth hormone synthesis and release, with downstream IGF-1 elevation. Catalogue material sold as CJC-1295 most often means this drug affinity complex form; the term is used inconsistently, and buyers should confirm from the certificate of analysis whether the DAC group is present, since the no-DAC form has a completely different duration of action.

Targets: GHRH receptor.

Origin: Stabilized GHRH(1–29) analog; DAC form is albumin-binding.

## Properties

- Molecular formula: C165H269N47O46
- Molecular weight: 3,647.2 g/mol
- CAS number: 446262-90-4
- Half-life: ~6–8 days (estimated 5.8–8.1 days in healthy adults after subcutaneous injection)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Early or uncontrolled human studies
- Human trials: 2
- Controlled human trials: 0
- Preclinical sources: 0
- Latest source: 2006

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. 2006. Human study (early or uncontrolled). Population: Healthy adults. Growth hormone and IGF-1 secretion, safety and tolerability [Source](https://pubmed.ncbi.nlm.nih.gov/16352683/)
2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. 2006. Human study (early or uncontrolled). Population: Healthy adults. Whether pulsatile GH secretion persists during continuous stimulation [Source](https://pubmed.ncbi.nlm.nih.gov/17018654/)
3. NCT00267527 — A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. Human study (early or uncontrolled). Population: HIV patients with visceral obesity (n=120 planned). Visceral obesity in HIV. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT00267527)

### Registered trials

- [NCT00267527](https://clinicaltrials.gov/study/NCT00267527)

## Safety

Side effects: Flushing; Water retention; Paresthesias; Injection-site reactions.

Risks: WADA S2 prohibited; IGF-1 elevation concerns.

Contraindications: Not recommended with diabetes; Avoid before surgery.

Human safety basis: Limited human reports

Key limitations: No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

CJC-1295 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is CJC-1295?

GHRH analog. Catalog “CJC-1295” often means the DAC (Drug Affinity Complex) form that extends half-life via albumin binding. Not FDA-approved. WADA S2 (GHRH analogues). CJC-1295 is a GHRH analog based on GRF(1-29) carrying four amino-acid substitutions that resist dipeptidyl peptidase-4 cleavage, plus a maleimidopropionyl group at the C-terminus. That reactive group forms a covalent bond with cysteine-34 of circulating serum albumin after injection, creating a long-lived depot and extending the half-life from minutes to days.

### What are the side effects of CJC-1295?

CJC-1295 has only limited human data, so its side-effect profile is not well established. Effects recorded on this profile include flushing, water retention, paresthesias and injection-site reactions. Cautions recorded on this profile: not recommended with diabetes and avoid before surgery. It is on the WADA Prohibited List for athletes. This is reference information, not medical advice.

### How does CJC-1295 work?

CJC-1295 is a GHRH analog based on GRF(1-29) carrying four amino-acid substitutions that resist dipeptidyl peptidase-4 cleavage, plus a maleimidopropionyl group at the C-terminus. That reactive group forms a covalent bond with cysteine-34 of circulating serum albumin after injection, creating a long-lived depot and extending the half-life from minutes to days.

### Is CJC-1295 FDA approved?

No. CJC-1295 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A nomination: Previously in Category 2; nomination withdrawn by the nominators.

### What is the half-life of CJC-1295?

CJC-1295 (with DAC) has an estimated half-life of 5.8–8.1 days in healthy adults after subcutaneous injection (Teichman et al., 2006), because it binds covalently to circulating albumin. Half-life describes how long the compound persists in circulation, not how long any effect lasts; the no-DAC form is a different, short-acting molecule.

### Is CJC-1295 banned in sport?

CJC-1295 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to CJC-1295?

Compounds most often compared with CJC-1295 include Sermorelin, Tesamorelin, CJC-1295 (no DAC) / Mod GRF(1-29) and CJC-1295 (no DAC) + Ipamorelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — J Clin Endocrinol Metab, 2006](https://pubmed.ncbi.nlm.nih.gov/16352683/)
- [Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog — J Clin Endocrinol Metab, 2006](https://pubmed.ncbi.nlm.nih.gov/17018654/)
- [An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma — Drug Test Anal, 2019](https://pubmed.ncbi.nlm.nih.gov/30489688/)
- [The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Front Endocrinol (Lausanne), 2026](https://pubmed.ncbi.nlm.nih.gov/42395176/)
- [Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects — Growth Horm IGF Res, 2009](https://pubmed.ncbi.nlm.nih.gov/19386527/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
